Bristol-Myers Squibb (NYSE:BMY) Expected to Post FY2024 Earnings of $0.57 Per Share

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Investment analysts at Zacks Research issued their FY2024 earnings per share estimates for Bristol-Myers Squibb in a research note issued on Thursday, May 9th. Zacks Research analyst E. Bagri expects that the biopharmaceutical company will earn $0.57 per share for the year. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $0.59 per share. Zacks Research also issued estimates for Bristol-Myers Squibb's Q1 2025 earnings at $1.79 EPS, Q2 2025 earnings at $1.77 EPS, Q4 2025 earnings at $1.76 EPS, FY2025 earnings at $6.94 EPS and Q1 2026 earnings at $1.52 EPS.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same quarter in the prior year, the company earned $2.05 earnings per share. The firm's quarterly revenue was up 4.7% compared to the same quarter last year.

Several other brokerages also recently weighed in on BMY. Wells Fargo & Company raised their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an "equal weight" rating in a report on Thursday, April 18th. BMO Capital Markets dropped their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a "market perform" rating on the stock in a research report on Friday, April 26th. Societe Generale cut Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research report on Monday, March 11th. Redburn Atlantic cut Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. Finally, William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $60.00.

Bristol-Myers Squibb Stock Up 0.3 %

Shares of NYSE:BMY traded up $0.12 on Monday, hitting $45.06. 11,809,862 shares of the company traded hands, compared to its average volume of 15,568,044. Bristol-Myers Squibb has a 52 week low of $43.33 and a 52 week high of $68.46. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The stock has a 50 day simple moving average of $49.72 and a 200-day simple moving average of $50.23. The company has a market cap of $91.34 billion, a PE ratio of -14.52, a PEG ratio of 15.19 and a beta of 0.45.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in BMY. OFI Invest Asset Management purchased a new position in shares of Bristol-Myers Squibb during the 3rd quarter valued at about $25,000. Milestone Investment Advisors LLC bought a new stake in Bristol-Myers Squibb during the 3rd quarter valued at approximately $27,000. Northwest Financial Advisors bought a new stake in Bristol-Myers Squibb during the 4th quarter valued at approximately $27,000. ESL Trust Services LLC bought a new stake in Bristol-Myers Squibb during the 1st quarter valued at approximately $27,000. Finally, Blue Bell Private Wealth Management LLC raised its stake in Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 200 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.33%. Bristol-Myers Squibb's payout ratio is currently -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.